Clinical Performance Guideline
Neonatal Resource Services
Early-Onset Neonatal Sepsis

Purpose: To provide guidelines to determine the optimal course of treatment and subsequent case management of early-onset neonatal sepsis (EONS).

Target Client Population: This guideline applies to term and late preterm neonates ≥ 34 weeks gestation who have clinical evidence of suspected or confirmed early-onset sepsis with a planned treatment course of antibiotics. Symptoms of neonatal sepsis may be non-specific but are rarely subtle.

Background
Neonatal sepsis is common in the newborn period and is a major cause of morbidity and mortality. Infection may be acquired in utero through the transplacental or transcervical route, during delivery or after birth. Symptoms of neonatal sepsis are variable but may include disturbances/alterations in feeding, respirations, cardiovascular status, temperature, activity or urination. Neonatal sepsis may be categorized as early-onset sepsis (EOS) or late-onset sepsis (LOS).

There is variability in defining early-onset neonatal sepsis with a range from ≤72 hours up to 7 days after birth. Risk factors for EOS include maternal GBS colonization (especially if not treated during labor), prematurity, prolonged rupture of membranes, preterm rupture of membranes, chorioamnionitis, and maternal urinary tract infection. The primary pathogens causing early-onset neonatal sepsis in the United States are group B streptococcus (GBS) and Escherichia coli (E. coli). Over the past 30 years, the implementation of universal maternal screening for GBS with intrapartum antibiotic prophylaxis has reduced the incidence of early onset neonatal GBS sepsis from 1.5 to 0.3/1,000 live births. (Oh, 2013)

There is significant variation in antibiotic use with antibiotic administration often unwarranted, prompting judicious use and timely discontinuation in promoting good stewardship. (Schulman, 2015)

Treatment Criteria
Clinical evidence in the medical literature supports the following:

- Newborns who exhibit signs of early-onset sepsis should have the following evaluation performed:
  - Blood culture
  - CBC with WBC differential and platelet count
  - Lumbar puncture if the infant can tolerate this procedure
  - Chest x-ray if the infant is presenting with altered respiratory status

- Newborns who exhibit signs of early-onset sepsis should usually have antibiotic therapy initiated with broad-spectrum agents of ampicillin and an aminoglycoside until the causative pathogen is identified. Then antimicrobial treatment should be narrowed to the specific pathogen(s) based on culture and sensitivity results.

- Asymptomatic newborns whose mothers have suspected chorioamnionitis
should have the following evaluation and treatment performed:

- Blood culture
- CBC with WBC differential and platelet count
- Antibiotic therapy initiated with broad-spectrum agents effective against the pathogens which commonly cause neonatal sepsis. Antibiotic therapy should be discontinued once the 48 hour blood culture results are known. Persistently abnormal laboratory data (CBC and/or CRP) may justify a longer treatment course. (Polin, 2012) Any abnormal CBC result obtained following birth should be corroborated at 6-12 hours of age to substantiate antibiotic treatment beyond 48 hours of life in an asymptomatic infant. (CDC, 2010)

- There is lack of data to support antibiotic treatment beyond 48 hours in an asymptomatic infant born to a woman with chorioamnionitis when the blood culture is negative and CBC/CRP is normal.
- Placenta examination leading to a diagnosis of histologic chorioamnionitis does not contribute to the diagnosis of early onset sepsis in term infants. (Cuna, 2014)
- Asymptomatic infants either <37 weeks gestation or with ruptured membranes ≥ 18 hours whose mothers did not receive adequate GBS prophylactic antibiotics when indicated should have the following evaluation performed:
  - Blood culture
  - CBC with WBC differential and platelet count (at birth and/or 6-12 hours of age)

- Asymptomatic infants > 37 weeks gestation with ruptured membranes < 18 hours whose mothers did not receive adequate GBS prophylactic antibiotics when indicated should receive hospital observation for ≥ 48 hours (CDC, 2010)

(Please refer to Appendix A for a detailed algorithm from the CDC, 2010)

- Antibiotic treatment for group B streptococci bacteremia without a defined focus should be administered for 10 days. For treatment of uncomplicated GBS meningitis, at least 14 days of antibiotic therapy should be administered. Gram-negative meningitis should be treated for either a minimum of 21 days or 14 days after a negative CSF culture. (Polin, 2012)
- Inability to obtain CSF for analysis should prompt consideration for radiographic-assisted guidance to support antibiotic therapy duration when repeated attempts have failed. This is particularly important if antibiotic therapy will be extended due to lack of CSF for analysis.
- Antimicrobial therapy should be discontinued at 48 hours if blood culture results are negative and the likelihood of sepsis is low. Abnormal CBC and/or CRP in an asymptomatic infant in the absence of maternal chorioamnionitis do not support antimicrobial therapy beyond 48 hours. (Polin, 2012; Benitz, 2015)
- Antibiotics may be continued for more than 48 hours if there is a positive blood/CSF culture, pneumonia or a high index of suspicion for presumed clinical sepsis.
  - Chest x-ray and symptoms that resolve within 24 hours is not typical
<table>
<thead>
<tr>
<th>Clinical Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>• In 2010, the Centers for Disease Control and Prevention (CDC) updated their guideline on Prevention of Perinatal Group B Streptococcal Disease. This document provides recommendations pertaining to the secondary prevention of early-onset GBS in newborns and includes guidance on full and limited diagnostic evaluations for possible sepsis, antibiotic therapy and infant observation. Laboratory analysis is not considered necessary for an asymptomatic infant whose mother received adequate intrapartum antibiotic prophylaxis.</td>
</tr>
<tr>
<td>• 2012 clinical report from the American Academy of Pediatrics attempted to establish an evidence-based approach to the Management of Neonates with Suspected or Proven Early-Onset Bacterial Sepsis. This document includes recommendations for diagnostic evaluations and the optimal treatment of these neonates.</td>
</tr>
<tr>
<td>• The CDC does not include the measurement of acute phase reactants such as C-reactive protein (CRP) in their recommendations for full or limited sepsis evaluations due to the low sensitivity and specificity for detection of neonatal sepsis. (2010)</td>
</tr>
<tr>
<td>• Polin et al (2012) discussed the use of acute-phase reactants in evaluating the neonate with suspected bacterial sepsis. They indicate normal CRP measurements may identify infants at low risk for bacterial sepsis but these values should not be used to determine the duration of antibiotic therapy in infants with elevated levels.</td>
</tr>
<tr>
<td>• A systematic analysis by Meem et al (2011) identified C-reactive protein as one of the most widely studied biomarkers for neonatal infections but the methodologies and study designs of this research were highly variable.</td>
</tr>
<tr>
<td>• A prospective study by Benitz et al (1998) evaluated neonates being treated for sepsis in three separate facilities. Serial CRP levels were performed on these infants at initial evaluation and on each of the next two mornings. The authors determined that the CRP level drawn on the morning after the initial evaluation had the highest sensitivity for proven or probable sepsis. They concluded two normal CRP levels, performed 24 hours apart at 8-48 after presentation, could identify infants at low risk for neonatal sepsis.</td>
</tr>
<tr>
<td>• Sivanandan et al (2011) indicate the use of ampicillin and an aminoglycoside is the recommended initial therapy in infants with suspected early-onset bacterial sepsis and/or meningitis where GBS and E. coli are the predominant organisms. They also conclude there is inadequate evidence from randomized trials to recommend any particular agent(s) for the treatment of late-onset sepsis.</td>
</tr>
</tbody>
</table>
| • Cuna et al (2014) investigated whether histologic chorioamnionitis (HCA) was associated with early onset clinical sepsis in the term newborn population. A retrospective record review of 3,417 term infants identified 3,029 infants who were asymptomatic with no risk factors for sepsis and 388 infants with risk factors and/or clinical signs of suspected sepsis who were admitted to NICU. Among the asymptomatic cohort admitted to the normal newborn nursery, 9.4% had evidence of HCA and none of these infants developed early onset clinical sepsis. The authors reported that an isolated finding of HCA in a...
• Sarker et al (2014) performed a retrospective review to evaluate whether intrapartum antibiotic therapy delayed the growth of organisms in blood cultures obtained for suspected early-onset neonatal sepsis. Based on the data obtained over a 13.5 years’ time period, no difference in the incubation time to blood culture positivity was identified between infants with blood culture-proven early-onset sepsis whose mothers received intrapartum antibiotic therapy and those infants whose mothers did not. The authors concluded the utilization of maternal intrapartum antibiotic treatment did not result in a delay in blood culture positivity for early-onset neonatal sepsis.

• A retrospective cohort study by Berardi et al (2014) was performed to assess how physical examination alone compared with physical examination in conjunction with laboratory evaluation in well-appearing infants ≥ 35 weeks’ gestation at risk for early onset sepsis (EOS). The infants who were evaluated utilizing physical examination alone were found to have received less unnecessary antibiotics with a shorter hospitalization than the infants evaluated with adjunctive laboratory testing. EOS symptoms presented earlier than initial laboratory test results in 42/44 infants and severe EOS was diagnosed within the first six hours of life in all of the neonates evaluated. The authors also did not identify any increase in severe complications or risk of illness after hospital discharge of the physical examination alone cohort.

• A review by Du Pont-Thibodeau et al (2014) outlined the management of neonatal sepsis in term newborns. The authors indicated there is consensus regarding the initiation of antibiotic therapy when neonatal sepsis is suspected; however, there is lack of consensus regarding the timing of antibiotic discontinuation and no clear consensus on the overall management of term neonates with sepsis. This document stresses the need for additional well-designed randomized controlled trials in order to develop evidenced-based guidelines for neonatal sepsis management.

• A retrospective cohort study by Schulman et al (2015) evaluated antibiotic use in 52,061 NICU infants in California during 2013. The authors identified a 40-fold variation in the antibiotic prescribing practice throughout the 127 NICUs that were included in this study. Overuse of antibiotics was demonstrated among many of these units with administration for various conditions that lacked a well-defined indication.

• Benitz et al (2015) provided an overview of the current management guidelines from the CDC and AAP for suspected early-onset sepsis. The authors indicated neither laboratory testing nor identification of maternal risk factors is effective in identifying infants with early-onset sepsis at the current time. An isolated abnormal laboratory result such as a blood count or C-reactive protein level in a well-appearing infant with negative blood cultures should not justify continuation of antibiotic therapy beyond 48 hours.
Appendix A

This algorithm relates to secondary prevention of early-onset GBS among newborns (Centers for Disease Control and Prevention, 2010)
Bibliography


American Academy of Pediatrics Committee on Fetus and Newborn and ACOG Committee on Obstetric Practice; Riley LE & Stark AR, editors. Guidelines for Perinatal Care, 7th ed. 2012.


Terrin G. Ranitidine is associated with infection, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics, January 2012:129(1).


Revision History
The following are approved changes incorporated into the revision numbers indicated below.

<table>
<thead>
<tr>
<th>Revision</th>
<th>Date</th>
<th>Description of Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>V1.0</td>
<td>05/16/2013</td>
<td>New guideline (MB)</td>
</tr>
<tr>
<td>V2.0</td>
<td>05/01/2014</td>
<td>Job Aid revised into Medical Necessity Clinical Guideline eliminating information on late-onset sepsis. (CE)</td>
</tr>
<tr>
<td>V3.0</td>
<td>05/03/2015</td>
<td>Annual review. (CE)</td>
</tr>
</tbody>
</table>